MDMA getting used to deal with post-traumatic stress dysfunction (PTSD) has turned out to be fairly profitable.

It's reported that 76 per cent of the 28 concerned in a Phase Two trial undertaken in Colorado did not meet the scientific diagnostic standards of PTSD 12 months on from receiving therapy.

Treatment consisted of a pair of two day-long MDMA-led periods with integrative remedy periods. A 3rd MDMA therapy session was additionally held.

The Multidisciplinary Association for Psychedelic Studies (MAPS) are finishing up the trials. Phase Three kicked off in September this 12 months, involving between 200 and 300 individuals within the United States, Canada and Israel. These are anticipated to go on for 2 years.

It's hoped the US Food and Drug Administration will approve MDMA's use for PTSD therapy by 2021.

[Via: New Atlas]

[Photo: MDMA Team]

Dave Turner is Mixmag's Digital News Editor, observe him on Twitter